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Abstract
Purpose The aim of this study was to investigate the expression of liver X receptors α/β (LXR) in primary breast cancer 
(BC) tissues and to analyze its correlations with clinicopathological parameters including patient survival.
Methods In a well-characterized cohort of 305 primary BC, subcellular distribution of LXR was evaluated by immunohis-
tochemistry. Correlations with clinicopathological characteristics as well as with patient outcome were analyzed.
Results LXR was frequently localized in both nuclei and cytoplasms of BC cells, with stronger staining in nuclei. Total 
and nuclear LXR expression was positively correlated with ER and PR status. Overall survival analysis demonstrated that 
cytoplasmic LXR was significantly correlated with poor survival and appeared as an independent marker of poor prognosis, 
in stage I but not in stage II–III tumors
Conclusion Altogether, these data suggest that cytoplasmic LXR could be defined as a prognostic marker in early stage 
primary BC.
Keywords Breast cancer · Early stage · Prognostic marker · LXR · Subcellular location
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Abbreviations
ABCA1  ATP-binding cassette transporter A1
BC  Breast cancer
CI  Confidence interval
DCIS  Ductal carcinoma in situ
ER  Estrogen receptor
FISH  Fluorescence in situ hybridization
HER2  Human epidermal growth factor receptor 2
HR  Hazard ratio
IHC  Immunohistochemistry
IRS  Immunoreactive score
LMU  Ludwig-Maximilians-University
LXR  Liver X receptor
cM  Metastasis
NR  Nuclear receptor
NST  Non-special type
OS  Overall survival
PBS  Non-special type
pN  Lymph-node status
PPAR  Peroxisome proliferator-activated receptor
PR  Progesterone receptor
pT  Tumor size
ROC-curve  Receiver-operating characteristic curve
RXR  Retinoid X receptor
THR  Thyroid hormone receptor
Introduction
Breast cancer (BC) has surpassed lung cancer as the most 
frequent diagnosed cancer worldwide in 2020 and is still the 
leading cause of cancer death among women (Sung et al. 
2021). Therapeutic strategies for BC are defined according 
to the immunohistochemical detection of tumor biomarkers 
which include estrogen receptor (ER), progesterone recep-
tor (PR), epidermal growth factor receptor 2 (HER2), and 
Ki67 (Harbeck et al. 2019). Systemic therapy approaches, 
including endocrine therapy, anti-HER2 therapy, and chemo-
therapy, have achieved success in improving clinical out-
comes of early BC patients (Harbeck and Gnant 2017; Pondé 
et al. 2019).
However, many early stage patients suffer long-term 
relapse or metastasis after routine treatments. Therefore, 
identification of novel biomarkers is necessary for advances 
in individualized and/or combined BC therapies. Among the 
early stage primary BC which is expected to have a good 
prognosis according to the above-mentioned markers, a spe-
cial need exists for new markers to identify the subgroup of 
patients that will eventually relapse from their disease.
Beside ER and PR, other nuclear receptors (NR) play 
a role in BC, as we and other have reported earlier (Bock 
et al. 2014; Ditsch et al. 2012; Doan et al. 2017; Heublein 
et al. 2017; Jalaguier et al. 2017; Jeschke et al. 2019; Shao 
et al. 2020a, 2020b; Zhang et al. 2017). Liver X receptors 
(LXRs) belong to the NR superfamily (Wang and Tontonoz 
2018) and have two isotypes, LXRα and LXRβ (encoded by 
the NR1H3 and NR1H2 gene, respectively). LXRα is highly 
expressed in adipose tissue, liver, adrenal glands, lungs, 
and gastrointestinal tract, while LXRβ is widely expressed 
(Repa and Mangelsdorf 2000). Upon activation by ligands, 
LXRs heterodimerize with retinoid X receptors (RXRs) and 
bind to target gene promoters, resulting in the regulation of 
various cellular parameters such as cholesterol synthesis and 
transport, glucose homeostasis, inflammatory, and immune 
responses (Bilotta et al. 2020; Lin and Gustafsson 2015).
LXR are also important actors in cancer biology. Indeed, 
previous studies revealed that natural LXR ligands (namely 
25- and 27-hydroxycholesterol) play an important role in 
lung and breast cancer by promoting invasion, migration, 
and metastasis through an LXR-dependent pathway (Chen 
et al. 2017; Nazih and Bard 2020; Nelson et al. 2013). None-
theless, studies based on LXR activation using the synthetic 
agonists T0901317 and/or GW3965 reported antineoplastic 
effects in various cancer types (Derangère et al. 2014; Lou 
et al. 2019; Pommier et al. 2010; Scoles et al. 2010; Vedin 
et al. 2009; Wang et al. 2019; Zhong et al. 2020). In various 
LXR-positive human BC cell lines, LXR agonists inhibited 
cell proliferation and increased p53 protein level (Vedin 
et al. 2009).
Moreover, LXR expression was reduced in liver and 
prostate cancers as compared to the adjacent normal tissues, 
indicating that LXR expression decreases during carcino-
genesis (Chen et al. 2020; Long et al. 2018). However, little 
is known about LXR expression and its prognostic value in 
breast cancer.
In the present study, we analyzed LXRα/β expression by 
immunohistochemistry (IHC) in a well-characterized cohort 
of 305 primary BC patients. We quantified LXR levels both 
in the nuclear and cytoplasmic compartments, and analyzed 




All samples (n = 305, two cases from one patient with bilat-
eral BC) in this retrospective analysis were collected at the 
Department of Obstetrics and Gynecology of the Ludwig-
Maximilians-University Munich, Germany between 2000 
and 2002. This study was approved by the Ethical Commit-
tee of the Medical Faculty, Ludwig-Maximilian-University, 
Munich, Germany (approval number 048-08; 18th of March 
2008) and informed consent was obtained from all patients. 
Patient data obtained from the Munich Cancer Registry were 
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pseudonymized and samples were encoded during experi-
ments and statistical analysis. All clinical diagnostic and 
therapeutic procedures were completed before this study. 
All tumors were evaluated according to UICC TNM clas-
sification, including tumor size (pT), lymph-node involve-
ment (pN), and distant metastasis (cM). Tumor grade was 
confirmed by an experienced pathologist (Dr. D. Mayr) of 
the LMU Department of Pathology, according to a modifi-
cation of Elston and Ellis grading proposed by Bloom and 
Richardson. ER, PR, HER2, and Ki67 were determined by 
an experienced pathologist (LMU Department of Pathology) 
at first diagnosis using immunohistochemistry. For ER and 
PR staining, tissues showing nuclear staining in more than 
10% of tumor cells were considered as hormone receptor-
positive. HER2 expression was analyzed with an automated 
staining system (Ventana; Roche, Mannheim, Germany), 
according to the manufacturer’s instructions. Cases were 
regarded as negative for 0 or 1 + score, and positive for 3 + 
scores. All cases with 2 + scores needed a further evalua-
tion, i.e., fluorescence in situ hybridization (FISH) testing. 
Ki67 cut-off used to differentiate luminal A from luminal B 
tumors (all HER2-negative) was 14% as commonly used at 
the time of diagnosis.
Immunohistochemistry (IHC)
Immunohistochemical staining for LXR was performed as 
previously described (Jeschke et al. 2019; Müller et al. 2019; 
Shao et al. 2020a, 2020b; Sixou et al. 2018). Briefly, whole 
tissue sections were cut and prepared from paraffin-embed-
ded BC samples using standard protocols. After deparaffi-
nizing in xylol for 20 min, endogenous peroxidase reaction 
was blocked with 3% hydrogen peroxide in methanol. Next, 
slides were rehydrated with a series of descending alcohol 
dilution and then boiled in a pressure cooker for 5 min, and 
immersed in sodium citrate buffer. Phosphate-buffered saline 
(PBS) was used for all washes and sections were incubated 
in blocking solution (ZytoChem Plus HRP Polymer System 
Kit, ZYTOMED Systems GmbH, Berlin, Germany) before 
incubation with primary antibody against LXR (LS-B262, 
Lifespan Biosciences, WA, USA) with a 1:200 dilution 
for 16 h at 4 °C. The antibody used was raised against A 
synthetic peptide made to an internal portion of the human 
LXR protein sequence (between residues 50–150), result-
ing in specificity against both LXRα and LXRβ isoforms. 
After incubation with a biotinylated secondary anti-rabbit 
IgG antibody, and with the associated avidin–biotin–per-
oxidase complex (both Vectastain Elite ABC Kit; Vector 
Laboratories, Burlingame, CA, USA), visualization was 
performed with substrate and chromogen 3, 3-diamino-
benzidine (DAB; Dako, Glostrup, Denmark). Negative and 
positive controls were used to assess the specificity of the 
immunoreactions. Negative controls (colored in blue) were 
performed in BC tissue by replacement of the primary anti-
bodies by species-specific (rabbit/mouse) isotype control 
antibodies (Dako, Glostrup, Denmark). Appropriate positive 
controls (placenta samples) were included in each experi-
ment. Sections were counterstained with acidic hematoxylin, 
dehydrated and immediately mounted with Eukitt (Merck, 
Darmstadt, Germany) before manual analysis with a Diaplan 
light microscope (Leitz, Wetzlar, Germany) with 25× magni-
fication. Pictures were obtained with a digital CCD camera 
system (JVC, Tokyo, Japan).
The staining of LXR was assessed according to a semi-
quantitative immunoreactive score (IRS), determined by 
multiplication of the positive cell proportion score (0 = 0%, 
1 = 1–10%, 2 = 11–50%, 3 = 51–80%, and 4 = 81–100% 
stained cells) and the staining intensity score (0 = nega-
tive, 1 = weak, 2 = moderate, and 3 = strong). As previ-
ously described for RIP140, PPARγ, and THRβ1 (Shao 
et al. 2020a, 2020b), LXR cytoplasmic and nuclear staining 
results were evaluated in parallel, with a separate determi-
nation of cytoplasmic IRS and nuclear IRS. Total IRS was 
calculated by the sum of cytoplasmic and nuclear IRS. For 
all other markers, staining and IRS were determined in the 
whole cells, without differentiation of nuclear and cyto-
plasmic staining. A total of hundred cells (three spots with 
around 30 cells each) were analyzed for each sample and the 
IRS corresponded to the mean of the IRS determined on the 
three spots by two independent blinded observers. Discord-
ant cases were re-evaluated by both observers together. After 
re-evaluation, both observers agreed on the result.
Statistical and survival analysis
Receiver-operating characteristic (ROC) curve analyses were 
performed to calculate the optimal cut-off values between 
low and high LXR expression, based on the maximum dif-
ferences of sensitivity and specificity. The threshold deter-
mined regarding OS was an IRS > 2.5 for nuclear LXR, > 5 
for cytoplasmic LXR and > 8.5 for total LXR, which were 
used to determine the percentages of tumors expressing low 
or high LXR levels described in Table 2. Correlation analy-
ses presented in Tables 3 and 4 were performed by calculat-
ing the Spearman’s-Rho correlation coefficient (p values of 
Spearman’s-Rho test presented).
Survival times were compared by Kaplan–Meier graph-
ics and OS differences were tested for significance using the 
chi-square statistics of the log-rank test. Data were assumed 
to be statistically significant in the case of p value < 0.05. 
Kaplan–Meier curves and estimates were then provided for 
each group and each marker. The p value and the number 
of patients analyzed in each group are given for each chart.
Statistical analyses above were performed using SPSS 
25 (IBMSPSS Statistics, IBM Corp., Armonk, NY, USA). 
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For all analyses, p values below 0.05 (*), 0.01 (**), or 
0.001 (***) were considered statistically significant.
Results
Expression of LXR in primary BC tissues
LXR expression was assessed by IHC in a cohort of 305 
primary BC samples (with clinical characteristics sum-
marized in Table 1). We used an antibody directed to both 
LXRα and LXRβ isoforms, to focus on the importance 
of the subcellular expression of both isoforms. Among 
these samples, one bilateral primary BC was regarded 
as two individual cases. During follow-up, 40 patients 
have experienced a local recurrence, 58 have developed 
distant metastases, and 88 have died. Median age at initial 
diagnosis was 57.8 ± 0.7 years (range 26.7–94.6 years) 
and median follow-up time was 125 ± 38.6 months (range 
1–153 months).
LXR immunoreactivity was present in both nucleus 
and cytoplasm of cancer cells. Examples of LXR 
staining from 5 patients are displayed in Fig. 1, with 
nucleo:cytoplasmic immunoreactive score (IRS) ratio 
indicated in each panel. Extreme (0:0 or 12:8) and inter-
mediate (6:6) IRS were shown in panels A–C all showing 
equivalent distribution of LXR staining in the nuclear 
and cytoplasmic compartments. Besides, tumors with low 
nuclear and high cytoplasmic LXR expression (0:6) or 
with high nuclear and low cytoplasmic IRS (12:0) were 
also observed and are exemplified in panels D and E, 
respectively.
Distribution and correlation of LXR expression were 
analyzed in the whole cohort (Table 2). The mean IRS val-
ues of nuclear and cytoplasmic LXR expression were 5.11 
and 3.05, respectively, demonstrating that LXR expression 
was stronger in the nucleus than in the cytoplasm. Both 
nuclear and cytoplasmic LXR expression was detected in 
a majority of BC samples, since only 15.41% and 28.52% 
of the tumors expressed no detectable nuclear and cyto-
plasmic LXR, respectively (Table 2).
Based on IRS cut-offs defined by performing an ROC-
curve analysis for OS, all patients were divided into low 
and high expression subgroups. Based on these nuclear 
and cytoplasmic LXR cut-off values, an inverse distribu-
tion of BC was noticed, with a majority of samples exhib-
iting a high nuclear IRS (73.77% of the tumors) and a 
low cytoplasmic one (77.70%). Total LXR was positively 
correlated with nuclear and cytoplasmic (p = 4.23 ×  10−75 
and 1.84 ×  10−38, respectively), and a positive correlation 
(p = 0.012) was also detected between nuclear and cyto-
plasmic LXR expression.
Table 1  Clinical and pathological characteristics of all patients
Clinical and pathological characteristics a n =  305b %
Age, median (years) 57.88
Follow-up, average (months) 110.22
Median 125
Histologyc
    Invasive lobular 40 13.11
    Invasive medullar 10 3.28
    Invasive mucinous 4 1.31
    No special type (NST) 160 52.46
    DCIS with NST 79 25.90
    Unknown 12 3.93
Focality
    Unifocal 167 54.75
    Multifocal and/or multicentric 138 45.25
ER status
    Positive 246 80.66
    Negative 59 19.34
PR status
   Positive 179 58.69
   Negative 126 41.31
HER2 status
   Positive 35 11.48
   Negative 268 87.87
   Unknown 2 0.66
Molecular subtype (IHC)
    Luminal A (Ki67 ≤ 14%) 169 55.41
    Luminal B (Ki67 > 14%) 61 20.00
    HER2 positive 26 8.52
    HER2 non-luminal 8 2.62
    Triple negative 39 12.79
    Unknown 2 0.66
Grade
   I 15 4.92
   II 102 33.44
   III 45 14.75
   Unknown 143 46.89
Staging
   Stage I 135 44.26
   Stage II 138 45.24
   Stage III 16 5.25
    Unknown 16 5.25
Tumor size
   pT1 192 65.31
   pT2 86 29.25
   pT3 4 1.36
   pT4 12 4.08
   Unknown 11 3.61
Lymph-node metastasis
   Yes 125 40.98
   No 164 53.77
   Unknown 16 5.25
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Correlation between LXR expression and clinical 
parameters
Using Spearman’s-Rho test, we analyzed the correlation 
between LXR expression and known clinicopathological 
features, including age, tumor size (pT), lymph-node status 
(pN), metastasis (cM), histology, stage, tumor grade, ER, 
PR, and HER2 status. As shown in Table 3, total and nuclear 
LXR expression were positively correlated with ER and PR 
status, whereas they were not correlated with other aggres-
sive markers (pT, pN, cM, histology, stage, grade, and HER2 
status). It should be noted that at the time of diagnosis, grad-
ing was not available for 143 noninvasive lobular carcinoma 
(classified in the NST group in Table 1). No significant asso-
ciations were observed between cytoplasmic LXR and all 
parameters mentioned in Table 3.
Correlation between cytoplasmic LXR expression 
and patient OS
As described in Table 2, we optimized the IRS cut-off values 
of LXR by performing ROC-curve analysis and divided the 
patient cohort into low and high expressing subgroups for 
all survival analyses. Comparisons of patient OS according 
to LXR expression levels were subsequently calculated by 
Kaplan–Meier analyses. Considering the whole cohort, no 
statistically significant correlations of nuclear, cytoplasmic, 
or total LXR expression were found with patient outcome 
(Fig. 2). Nonetheless, the trend existed with a possible 
a All information given refers to the primary tumor
b One of 304 patients are bilateral primary BC, so we deal with the 
tumor as individual one (n = 305)
c NST include the formerly called “Invasive ductal” and “other” types; 
DCIS is for Ductal carcinoma in situ
Table 1  (continued)
Clinical and pathological characteristics a n =  305b %
Local recurrence
   Yes 40 13.11
   No 254 83.28
   Unknown 11 3.61
Distant metastases
    Yes 58 19.02
    No 236 77.38











5 0 µm5 0 µm
5 0 µm
Fig. 1  Immunohistochemical staining of LXR in BC samples. 
LXR staining is illustrated for five patients with absent, intermedi-
ate, or high LXR expression. Examples of tumors with opposite 
nucleo-cytoplasmic expression of LXR are given in panels D and E. 
Nucleo:cytoplasmic IRS (immunoreactive score) ratios are indicated 
in each photomicrograph (×25 magnification) and scale bar equals 
50 μm
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favorable survival for the patients with low cytoplasmic 
LXR expression (p = 0.068).
We then then stratified patients in two subgroups, accord-
ing to staging (stage I vs stage II–III). As shown in Fig. 3B, 
no significant difference was observed in the subgroups of 
patients with stage II–III (p = 0.977), whereas in stage I sub-
group (Fig. 3A), patients with tumors showing a low level 
of cytoplasmic LXR expression had a significantly better 
outcome compared to those with a high level of cytoplasmic 
LXR (p = 0.001).
To better decipher this correlation with survival, we also 
stratify patients according to lymph-node status (negative vs 
positive) and tumor size (pT1 vs pT2-3). The correlation of 
cytoplasmic LXR with patient OS was significant in lymph-
node negative tumors (Fig. 3C p = 0.040) but not in the sub-
group of patients with tumors presenting lymph-node inva-
sion (p = 0.359). The correlation was even more significant 
in the subgroup of patient with pT1 tumors (p = 0.00032, 
Fig. 3E) and lost in the pT2-3 subgroup (p = 0.198, Fig. 3F).
As a control, we also analyzed OS according to the 
expression of RXR, the heterodimerization partner of LXR. 
No significant correlations with OS were found in the whole 
cohort or in the subgroups according to staging, lymph-node 
status, or tumor size (Supplementary Fig. 1). Altogether, 
these data demonstrated that cytoplasmic LXR expression 
is associated with poor prognosis in patients with early stage 
BC (i.e., with small and noninvasive tumors).
Cytoplasmic LXR expression as an independent 
prognostic parameter
Multivariate analyses were performed for the whole cohort 
and for the two subgroups according to staging (stage I vs 
stage II-III), using a Cox regression model with cytoplas-
mic LXR expression and other relevant clinicopathological 
characteristics, namely age at diagnosis, metastasis status, 
ER, and HER2 (Table 4). All parameters were demonstrated 
Table 2  Distribution and correlation of LXR expression
IRS cut-offs for low and high expression (defined using ROC-curve 
analysis) were defined by performing an ROC-curve analysis for OS
Correlations were statistically significant for p < 0.05 (*) or p < 0.001 
(***), using Spearman-Rho test using mean bilateral analysis
Total Nuclear Cytoplasmic
Mean IRS ± SE 8.16 ± 0.27 5.11* ± 0.20 3.05 ± 0.15
IRS range 0–20 0–12 0–12
IRS cut-off 8.5 2.5 5
Negative expression 32 (10.49%) 47 (15.41%) 87 (28.52%)
Low expression 161 (52.79%) 80 (26.23%) 237 (77.70%)
High expression 144 (47.21%) 225 (73.77%) 68 (22.30%)
Correlation coefficient
 Nuclear LXR 0.819*** 1.000 0.144*
 Cytoplasmic LXR 0.653*** 0.144* 1.000
Table 3  Correlation between LXR expression and clinicopathological 
markers
Correlations are statistically significant for p < 0.05 (*) or p < 0.01 
(**), using Spearman-Rho test
Total Nuclear Cytoplasmic
Age − 0.077 − 0.050 − 0.057
pT − 0.049 − 0.027 − 0.032
pN − 0.089 − 0.088 − 0.025
cM − 0.025 − 0.014 − 0.040
Histology 0.015 0.043 − 0.042
Stage − 0.055 − 0.006 − 0.059
Grade − 0.146 − 0.154 − 0.036
ER 0.137* 0.172*** 0.006
PR 0.116* 0.114* 0.037
HER2 0.016 − 0.040 0.083
Fig. 2  Kaplan–Meier analyses of patient overall survival (OS) in 
the whole cohort according to nuclear, cytoplasmic, and total LXR 
expression. OS Kaplan–Meier curves are presented according to total 
(A), nuclear (B), and cytoplasmic (C) LXR expression. The optimal 
IRS cut-off values for nuclear, cytoplasmic, and total LXR expression 
were determined as 2.5, 5, and 8.5, respectively. The number of cases 
for each group is indicated in each penal
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to be independent prognostic markers of OS for the whole 
cohort.
Interestingly, cytoplasmic LXR was regarded as an inde-
pendent prognostic marker in the whole cohort, but this cor-
relation was much stronger in the stage I subgroup, with 
hazard ratio of 1.871 (95% CI 1.156–3.030; p = 0.011) and 
7.172 (95% CI 2.764–18.611; p = 5.1 ×  10−5), respectively. 
In contrast, cytoplasmic LXR did not exhibit an independ-
ent prognostic value in the stage II–III subgroup. Similarly, 
cytoplasmic LXR was a strong independent prognostic 
marker in the pT1 subgroup (data not shown), but not in the 
pT2-3 subgroup, nor in the lymph-node negative or positive 
subgroups.
Discussion
Based on IHC staining analysis, the present study provides 
evidence for a differential subcellular distribution of LXR 
expression in primary BC, and is the first evaluation of its 
correlations with clinicopathological characteristics and 
patient survival.
Fig. 3  Kaplan–Meier analyses of patient overall survival for cytoplas-
mic LXR expression in subgroups according to tumor size, lymph-
node status, and staging. Overall survival (OS) curves are presented 
according to cytoplasmic LXR, for Stage I (A) and stage II–III (B) 
subgroups of patients, for either lymph-node negative (C) or positive 
(D) subgroups, and for the pT1 (E) and pT2-3 (F). The optimal IRS 
cut-off value of 5 was used and the number of cases for each group is 
indicated in each panel. Statistical significance is shown as p value 
from log-rank test (*p < 0.05; ***p < 0.001)
Table 4  Multivariate analysis of significant clinicopathological variables and of cytoplasmic LXR regarding OS in the whole cohort and in vari-
ous subgroups
HR hazard ratio, CI confidence interval, p p value
Correlations are statistically significant for p < 0.05 (*) or p < 0.01 (**), p < 0.001 (***)
Whole cohort (n = 279) Stage I (n = 121) Stage II-III (n = 145)
HR 95% CI p HR 95% CI p HR 95% CI p
Age 1.055 1.037–1.074 2.95 ×  10-9*** 1.067 1.026–1.109 0.001** 1.049 1.028–1.071 5 ×  106***
cM 5.692 3.666–8.836 9.27 ×  10-15*** 18.632 6.197–56.014 1.91 ×  10-7*** 4.801 2.789–8.264 1.50 ×  10-8***
ER 0.492 0.307–0.789 0.003** 0.248 0.093–0.659 0.005** 0.513 0.290–0.909 0.022*
HER2 1.824 1.033–3.220 0.038* 0.758 0.203–2.835 0.681 4.257 2.122–8.540 4.5 ×  10-5***
Cytoplasmic LXR 1.871 1.156–3.030 0.011* 7.172 2.764–18.611 5.1 ×  10-5*** 0.918 0.462–1.826 0.808
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We found that LXR was predominantly expressed in the 
nuclei of BC cells, but was also detected in their cytoplasm. 
LXRα expression was previously shown to be predominant 
in nuclei of hepatocellular carcinoma (Long et al. 2018), as 
LXRβ isoform in BC tissues (Le Cornet et al. 2020). Con-
sistent with our results, a previous study reported that LXRβ 
immunoreactivity, not LXRα, was detected both in nuclei 
and cytoplasm in pancreatic cancer samples, whereas only 
nuclear staining was present in normal pancreatic ductal 
epithelial tissues (Candelaria et al. 2014). Besides, LXRβ 
expression was predominantly localized in cytoplasm of 
gastric cancer cells (Wang et al. 2019) and of colon can-
cer cells but in nucleus of normal mucosa cells (Courtaut 
et al. 2015). In a recent study, only nuclear LXRβ, and not 
LXRα, was shown to be expressed in the nuclei of 96 triple-
negative BC (Pan et al. 2019). In a study focused on LXR 
intracellular distribution, unliganded LXRα was retained in 
nucleus whereas unliganded LXRβ was exported to cyto-
plasm (Prüfer and Boudreaux 2007). In addition, the quick 
non-genomic activity of LXRβ after activation by ligand 
induced pyroptosis in cytoplasm of colon cancer cells 
and then LXRβ translocated into nucleus to initiate tran-
scriptional activity (Derangère et al. 2014). Activation by 
T0901317, LXRβ translocated into nuclei and inhibited cell 
proliferation via the Wnt signaling pathway (Wang et al. 
2019). Thus, nuclear export of LXR may exist in malignant 
cells, and intracellular localization of LXR may play differ-
ent roles in carcinogenesis.
The link between subcellular localization of NR and BC 
progression seems important parameters in BC etiology. 
We have previously demonstrated that cytoplasmic PPARγ 
is predominantly detected in BC tissues and that it is cor-
related with poor outcome (Shao et al. 2020a). Besides, 
nuclear THRβ1 in BC tissue appeared to be a marker for 
poor prognosis, whereas its cytoplasmic form was correlated 
with favorable survival (Shao et al. 2020b). Transcriptional 
activity of NRs is mediated by their subcellular localization 
through a nuclear localization sequence or export sequence. 
The specific mechanisms and molecular consequences of 
the cytoplasmic location of various NRs still have to be 
investigated.
Correlation analysis between LXR expression and clin-
icopathological parameters indicated that nuclear and total 
LXR were positively related to ER and PR. A recent study 
indicated that ER-negative BC had a high transcription 
response to LXR agonists compared to ER-positive BC 
(Hutchinson et al. 2019). Besides, 27-hydroxycholesterol 
acted as not only an LXR ligand but also as an ER agonist. 
LXR action was accentuated by inhibition of ER signaling 
(McDonnell et al. 2014). Induction of Est, a transcriptional 
target gene of LXR, decreased estrogen level in mouse 
model, leading to suppression of BC progression (Gong 
et al. 2007). LXRα, LXRβ, and their corepressors have 
been shown to be differentially expressed in ER-positive 
vs ER-negative BC tumors (Nazih and Bard 2020). Taken 
together, further study of crosstalk with ER signaling path-
way is needed for LXR molecular mechanism in BC biology.
The present study is the first analysis of LXR expres-
sion and survival in BC, although correlations between LXR 
expression and patient outcome have already been analyzed 
in other cancers. Indeed, in stage II and III non-small-cell 
lung cancer patients, high LXRα expression was corre-
lated with a favorable outcome, regardless of its subcellular 
localization (Melloni et al. 2018). Considering the staining 
of nuclear with/without cytoplasmic forms in human colon 
cancer, positive LXR was associated with favorable OS 
(Yun et al. 2017). Moreover, hepatocellular cancer patients 
with high nuclear LXRα expression had long-term OS 
(Long et al. 2018). However, BC patients with higher level 
of LXR ligand target genes expression had an unfavorable 
outcome compared to those with lower levels (Nguyen-Vu 
et al. 2013). It is noteworthy that, in our study, cytoplasmic 
LXR was an independent prognostic factor for poor OS in 
the whole cohort, although no statistical significance was 
observed in Kaplan–Meier analysis.
Interestingly, cytoplasmic LXR was strongly correlated 
with poor OS in the stage I, pT1, and lymph-node negative 
subgroups. This correlation was confirmed by multivariate 
analysis in the stage I (and pT1) subgroup, which appeared 
stronger than that observed in the whole cohort. There-
fore, subcellular distribution of LXR expression appears as 
a parameter that needs to be taken into account in further 
studies of its mechanism or prognostic value in malignant 
tumors. Especially for luminal (ER/PR-positive and HER2-
negative) early stage BC, the main concern is to identify 
patients who need to receive also chemotherapy in addition 
to endocrine therapy (Harbeck et al. 2019). Next to more 
complex and expensive genomic signatures, IHC assays that 
enable identification of the subcellular location of relevant 
therapeutic markers may also be valuable. Cytoplasmic LXR 
as a strong and independent prognostic marker in the pT1 
subgroup may be an excellent candidate to explore.
Conclusion
In our primary BC cohort, LXR expression, although mostly 
localized in nuclei, was also detected in the cytoplasm. Cyto-
plasmic LXR correlated with poor OS in stage I, pT1, and 
lymph-node negative subgroups. Most importantly, cytoplas-
mic LXR had a strong and independent prognostic value 
regarding poor outcome only in early stage primary BC.
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